Adverum Biotechnologies Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.00
Dividend & YieldN/A$ (N/A)
Beta 1.09
Market capitalization 67.83M
Operating cash flow -115.43M
ESG Scores unknown

Company description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -2.27M -650k 1.58M -1.61M
Total Cashflows From Investing Activities 69.44M -68.07M -280.17M 78.71M
Net Borrowings -75k -112k -61k -240k
Total Cash From Financing Activities 69.95M 28.19M 355.99M 2.4M
Change To Operating Activities 649k 5.71M 11.14M 5.67M
Issuance Of Stock 71.22M 29.77M 358.09M 2.64M
Net Income -72.63M -64.49M -117.51M -145.54M
Change In Cash 85.43M -89.05M -3.47M -26.73M
Effect Of Exchange Rate
Total Cash From Operating Activities -53.96M -49.17M -79.29M -107.83M
Depreciation 1.75M 1.57M 4.16M 4.64M
Change To Account Receivables
Other Cashflows From Financing Activities
Change To Netincome 18.53M 8.68M 21.33M 29M
Capital Expenditures -809k -19.25M -11.84M -15.12M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 89.18M 89.18M 89.18M 89.18M
Income Before Tax -73.88M -64.49M -116.39M -145.54M
Net Income -72.63M -64.49M -117.51M -145.54M
Selling General Administrative 24.56M 28.38M 44.64M 63.38M
Gross Profit -48.52M -40.17M -73.31M -81.68M
Ebit -73.08M -68.55M -117.95M -145.06M
Operating Income -73.08M -68.55M -117.95M -145.06M
Interest Expense
Income Tax Expense -1.25M 1.11M
Total Revenue 1.61M 250k 7.5M
Cost Of Revenue 50.13M 40.42M 73.31M 89.18M
Total Other Income ExpenseNet -796k 4.06M 1.56M 101k
Net Income From Continuing Ops -72.63M -64.49M -117.51M -145.54M
Net Income Applicable To Common Shares -72.63M -64.49M -117.51M -145.54M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 12.33M 47.77M 48.22M 123.54M
Total Stockholder Equity 201.17M 174.96M 434.35M 316.19M
Other Current Liabilities 1.83M 2.54M 1.32M 3.33M
Total Assets 213.5M 222.73M 482.57M 439.73M
Common Stock 6k 7k 10k 10k
Other Current Assets
Retained Earnings -320.54M -385.03M -502.54M -648.08M
Treasury Stock -799k -725k -261k -714k
Cash 154.95M 65.9M 62.42M 34.2M
Total Current Liabilities 10.72M 19.41M 20.87M 21.32M
Other Stockholder Equity -799k -725k -261k -714k
Property, Plant, and Equipment 3.59M 45.85M 47.1M 119.06M
Total Current Assets 208.75M 175.87M 434.44M 317.14M
Net Tangible Assets 201.17M 174.96M 434.35M 316.19M
Net Receivables 5.71M
Accounts Payable 1.71M 4.1M 2.81M 1.39M


Insider Transactions

Here are the insider transactions of stock shares related to Adverum Biotechnologies Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
FISCHER LAURENT D M.D.Sale at price 1.07 per share.D2022-09-19Chief Executive Officer41.08k
SOPARKAR PETERSale at price 1.07 per share.D2022-09-19Chief Operating Officer13.3k
RILEY BRIGIT PH.D.Sale at price 1.07 per share.D2022-09-19Officer7.27k
SEYEDKAZEMI SETAREHSale at price 1.07 per share.D2022-09-19Officer6.06k
BECKMAN RICHARD L. M.D.Sale at price 1.07 per share.D2022-09-19Officer4.27k
SEYEDKAZEMI SETAREHStock Award(Grant) at price 0.00 per share.D2022-09-14Officer33.33k
BECKMAN RICHARD L. M.D.Stock Award(Grant) at price 0.00 per share.D2022-09-14Officer25k
BECKMAN RICHARD L. M.D.Stock Award(Grant) at price 0.00 per share.D2022-09-14Officer33.33k
SEYEDKAZEMI SETAREHPurchase at price 0.84 per share.D2022-05-23Officer20k
D'SOUZA RUPERTPurchase at price 0.83 - 0.86 per share.D2022-05-17Chief Financial Officer20k
BECKMAN RICHARD L. M.D.Purchase at price 0.82 per share.D2022-05-17Officer10k
SVORONOS DAWN APurchase at price 0.85 per share.D2022-05-16Director30k
FISCHER LAURENT D M.D.Purchase at price 1.11 per share.D2022-04-20Chief Executive Officer25k
SOPARKAR PETERPurchase at price 1.14 per share.D2022-04-19Chief Operating Officer21.93k
FISCHER LAURENT D M.D.Purchase at price 1.79 - 1.85 per share.D2021-12-09Chief Executive Officer25k
SCOPA JAMES PAULSale at price 2.18 per share.I2021-11-15Director50k
CLARK JULIESale at price 2.17 per share.D2021-09-30Officer4.77k
FISCHER LAURENT D M.D.Stock Award(Grant) at price 0.00 per share.D2021-08-06Chief Executive Officer680k
SOPARKAR PETERStock Award(Grant) at price 0.00 per share.D2021-08-06Chief Operating Officer220k
THEDINGA ANGELAStock Award(Grant) at price 0.00 per share.D2021-08-06Chief Technology Officer150k
CLARKE JULIEStock Award(Grant) at price 0.00 per share.D2021-08-06Officer120k
CLARK JULIEStock Award(Grant) at price 0.00 per share.D2021-08-06Officer120k
SVORONOS DAWN APurchase at price 10.02 per share.D2021-03-31Director20k
FISCHER LAURENT D M.D.Purchase at price 9.88 per share.D2021-03-24Chief Executive Officer10k
MACHADO PATRICKPurchase at price 9.92 per share.D2021-03-24Director10k
PATTERSON LEONE DSale at price 14.10 - 14.14 per share.D2021-02-09President12.53k
FISCHER LAURENT D M.D.Purchase at price 11.53 per share.D2021-01-15Chief Executive Officer8.6k
MACHADO PATRICKPurchase at price 11.52 per share.D2021-01-15Director10k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Adverum Biotechnologies Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Adverum Biotechnologies Inc

Here is the result of two systematic investment strategies applied to Adverum Biotechnologies Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Adverum Biotechnologies Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Adverum Biotechnologies Inc:

Adverum Biotechnologies Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -71.87% on the backtest period.

Performance at glance

Performance

-71.87 %

Latent gain

-1253.42 $

Invested capital

1744.02 $

Annualized return

-17.53 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Adverum Biotechnologies Inc

This is the result of two momentum investment strategies applied to Adverum Biotechnologies Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Adverum Biotechnologies Inc

The following chart shows all the entries opened by the momentum investment system on Adverum Biotechnologies Inc:

Adverum Biotechnologies Inc momentum entries
  • The first momentum investment strategy would give -59.56% of return on Adverum Biotechnologies Inc. That represents -2974.61$ of latent gain with 4994.21$ of employed capital.
  • The second momentum investment strategy would give -64.91% of return on Adverum Biotechnologies Inc. That represents -1619.92$ of latent gain with 2495.52$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-59.56 %

Latent gain

-2974.61 $

Invested capital

4994.21 $

Annualized return

-31.85 %
Performance at glance (2Q Momentum)

Performance

-64.91 %

Latent gain

-1619.92 $

Invested capital

2495.52 $

Annualized return

-17.93 %

Momentum equity curve on Adverum Biotechnologies Inc

The following chart shows the equity curve of the two momentum strategies applied to Adverum Biotechnologies Inc:

Adverum Biotechnologies Inc momentum equity

Note: the dividends potentially given by Adverum Biotechnologies Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Adverum Biotechnologies Inc

The following chart shows the employed capital evolution of the two momentum strategies on Adverum Biotechnologies Inc since the beginning:

Adverum Biotechnologies Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Adverum Biotechnologies Inc

Buy the dip entry openings on Adverum Biotechnologies Inc

Adverum Biotechnologies Inc

The performance achieved by the robo-advisor on Adverum Biotechnologies Inc is -66.89%. That represents -839.94$ of latent gain with 1255.74$ of employed capital. The following chart shows Adverum Biotechnologies Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Adverum Biotechnologies Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-66.89 %

Latent gain

-839.94 $

Invested capital

1255.74 $

Annualized return

-31.85 %

Equity curve of the strategy applied to Adverum Biotechnologies Inc

The following chart shows the result of the investment strategy applied to Adverum Biotechnologies Inc:

Adverum Biotechnologies Inc

Note: the dividends potentially given by Adverum Biotechnologies Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Adverum Biotechnologies Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Adverum Biotechnologies Inc:

Adverum Biotechnologies Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Adverum Biotechnologies Inc

In this section, I will compare the three previous investment strategies applied to Adverum Biotechnologies Inc.

Equity curve comparison on Adverum Biotechnologies Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Adverum Biotechnologies Inc investment strategy comparison

Employed capital comparison on Adverum Biotechnologies Inc

Adverum Biotechnologies Inc investment comparison

Performance comparison on Adverum Biotechnologies Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -71.87% -1253.42$ 1744.02$ -17.53%
Momentum 1 quarter -59.56% -2974.61$ 4994.21$ -15.43%
Momentum 2 quarters -64.91% -1619.92$ 2495.52$ -17.93%
Non-directional -66.89% -839.94$ 1255.74$ -31.85%
Annualized return comparison

Automatic investment

-17.53 %

Momentum 1Q

-17.93 %

Momentum 2Q

-17.93 %

Non-directional

-31.85 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Adverum Biotechnologies Inc:

Positive correlations

Most correlated stocks this year

  • Adverum Biotechnologies Inc

  • Most correlated stocks last 3 months

  • Adverum Biotechnologies Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • Computer Task Group Inc

  • Note: The algorithm computes the probability of correlation between Adverum Biotechnologies Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Adverum Biotechnologies Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Adverum Biotechnologies Inc
    Country United States
    City Redwood City
    Address 800 Saginaw Drive
    Phone 650 656 9323
    Website www.adverum.com
    FullTime employees 188
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker ADVM
    Market www.nasdaq.com

    Adverum Biotechnologies Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown